This paper investigated the effect of blood stabilization tube types (PAXgene and Tempus), RNA extraction methods, and reverse-transcription methods on the RNA yield and integrity and levels of three mRNAs and three microRNAs (miRNA, miR) in blood from patients with and without acute myocardial infarction (MI).
Comparison of whole blood RNA preservation tubes and novel generation RNA extraction kits for analysis of mRNA and MiRNA profiles.
Häntzsch M, Tolios A, Beutner F, Nagel D, Thiery J, Teupser D, Holdt LM
Purpose
Conclusion
For PAXgene specimens, significantly more RNA was obtained using the QIAsymphony and PAXgene kits than the Norgen Kit in both patient groups but there were no significant differences in RNA yield among kits for Tempus specimens. Significantly more RNA was obtained from specimens in Tempus Tubes than PAXgene Tubes in the control group, but no difference was found in the MI group. RNA integrity numbers (RIN) were comparable among extraction methods but tended to be lower when RNA was extracted with the Norgen Kit rather than the other methods. RNA extracted from PAXgene blood using the Norgen Kit had higher cycle threshold (CT) values for β-actin (ACTB), matrix metalloproteinase (MMP)-9, and arginase-1 (ARG-1) and lower CT values for miR-16 and miR-30b than RNA from Tempus blood or from PAXgene blood extracted using the other kits. mRNA CT values were higher when reverse-transcription was with Superscript VILO cDNA Synthesis Kit rather than miScript Reverse Transcription Kit. Contrastly, there was more variability in miRNA expression levels, with each miRNA affected differently by RNA extraction method used, tube type, or reverse-transcription method. As expected, MMP-9 and ARG-1 levels were increased in specimens from MI patients compared to controls, regardless of tube type. extraction method, or reverse-transcription method. Although more variable in extent, miR133a and miR1 levels were generally higher in MI patients than controls.
Studies (1)
Purpose
This study investigated the effect of blood stabilization tube types (PAXgene and Tempus), RNA extraction methods, and reverse-transcription methods on the RNA yield and integrity and levels of three mRNAs and three miRNAs in blood from patients with and without acute MI. Blood was collected into three PAXgene Blood RNA Tubes and three Tempus Blood RNA Tubes from 12 patients with MI and 35 patients without MI (control). Tubes were stored at room temperature for 2 h, followed by storage at -20°C for 24 h, and then -80°C for more than a week. Blood was thawed for 2 h at room temperature (PAXgene tubes) or 30 min at room temperature (Tempus tubes) before RNA extraction. RNA was extracted from blood in PAXgene tubes using the PAXgene Blood miRNA Kit, the Norgen Preserved Blood RNA Purification Kit II, or the QIAsymphony PAXgene Blood RNA Kit for fully automated RNA isolation on the QIAsymphony and extracted from blood in Tempus tubes using MagMAX for Stabilized Blood Tubes RNA Isolation Kit, Norgen Preserved Blood RNA Purification Kit I, or the MagMAX for Stabilized Blood Tubes RNA Isolation Kit for semi-automated isolation on the MagMAX Express-96 Magnetic Particle Processor. RNA concentration was assessed by spectrophotometry. RNA was frozen at -80°C and then quality was assessed using the Agilent Small RNA Kit on a Bioanalyzer 2100. RNA from 12 specimens (6 MI and 6 control) extracted using the Qiagen kits and Life Technologies kits was reverse-transcribed and quantified in the following ways: (1) reverse-transcribed with the miRScript Reverse Transcription Kit and mRNA quantified using QuantiTect Primer assays (mRNA), (2) reverse-transcribed with the miRScript Reverse Transcription Kit and miRNA quantified using the miScript Primer assay (miRNA), (3) reverse-transcribed with Supercripts Vilo cDNA Synthesis Kit and mRNA quantification using TaqMan assays, or (4) reverse-transcribed using TaqMan Small RNA assays and quantification using TaqMan miRNA assays. All cDNA was stored at -20°C until quantification.
Summary of Findings
For PAXgene specimens, significantly more RNA per g of blood was obtained using the QIAsymphony and PAXgene kits than the Norgen kit in patients with (P<10–5) and without MI (P<10–5), but there were no significant differences in RNA yield among kits for Tempus specimens. Significantly more RNA per g blood was obtained from specimens in Tempus tubes than PAXgene tubes in the control group (P=3.54 x 10-4) but no difference was found in the MI group. More RNA per g of blood was also obtained from the blood of patients in the MI group than the control group (P=5.3 x 10-9), regardless of tube type. Similar effects were found when yield of RNA was not normalized to input. RIN values were comparable among extraction methods but tended to be lower when RNA was extracted with the Norgen kits rather than the other methods (5.9-6.0 versus 6.0-8.6). RNA extracted from PAXgene blood using the Norgen Kit had higher CT values for ACTB, MMP9, and ARG1 and lower CT values for miR-16 and miR30b than RNA from Tempus blood or RNA from PAXgene blood extracted using the other kits (no statistics evaluated). mRNA CT values were higher when reverse-transcription was with Superscript VILO cDNA Synthesis Kit rather than miScript Reverse Transcription Kit. In contrast, there was more variability in miRNA expression levels, with each miRNA affected differently by RNA extraction method used, tube type, and reverse-transcription method. The CV for the three RNA transcripts were all below 1.0 regardless of tube type, extraction method, or reverse-transcription method except for ACTB and MMP9 when RNA was extracted from PAXgene tubes using the Norgen II Kit and reverse-transcribed using miScript. The CVs for miRNAs were also below 1.0 except for miR31 when reverse-transcription was with miScript. MMP9 and ARG1 levels were increased in specimens from MI patients compared to controls, regardless of tube type or extraction and reverse-transcription method. Although more variable in extent, miR133a and miR1 levels were generally higher in MI patients than controls.
Biospecimens
FluidBloodPreservation Types
Other PreservativePAXgeneFrozenDiagnoses
Cardiovascular DiseaseNot specifiedPlatforms
RNAAutomated electrophoresis/BioanalyzerRNASpectrophotometryRNAReal-time qRT-PCRPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Preaquisition Diagnosis/ patient condition Acute myocardial infarctionNo myocardial infarctionBiospecimen Acquisition Type of collection container/solution PAXgene blood RNA tubeTempus blood RNA tubeAnalyte Extraction and Purification Analyte isolation method MagMAX for Stabilized Blood Tubes RNA Isolation KitMagMAX for Stabilized Blood Tubes RNA Isolation Kit on the MagMAX Express-96 Magnetic Particle ProcessorNorgen Preserved Blood RNA Purification Kit INorgen Preserved Blood RNA Purification Kit IIPAXgene Blood miRNA KitQIAsymphony PAXgene Blood RNA Kit for fully automated RNA isolationSpectrophotometry Specific Data handling Normalized to g bloodNot normalizedReal-time qRT-PCR Specific Targeted nucleic acid ACTBARG1MMP9miR1miR133amiR16miR30bReal-time qRT-PCR Specific Technology platform QuantiTect Primer assaysTaqMan assaysmiScript Primer assayReal-time qRT-PCR Specific Template modification Reverse transcribed using TaqMan small RNA assaysReverse transcribed with Supercripts Vilo cDNA Synthesis kitReverse transcribed with miRScript Reverse Transcription kit